$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Maintenance of human-induced pluripotent stem cells
We used three hPSC lines (RIKEN-2F, 253G1, and KMUR001). We have optimized the maintenance protocol through daily manually performed experiments and further optimized the detailed programs through the seven preliminary experiments performed by the system. For example, shear stresses caused by the liquid speeds of the spit flow from different pipets handled by humans and the system are quite different; therefore, we optimized the time length of the enzymatic digestion and the number of pipetting for cell dispersion by the system.
Human induced pluripotent stem cells were maintained on a 10 cm dish coated with 0.5 µg/cm2 cell culture matrix with hiPSC culture medium (e.g., Neutristem or StemFit AK02N). For passage, the system was programmed to wash hiPSC three times with 5 mL of phosphate buffer saline without calcium (PBS[-]), then treat with 3 mL of TrypLE express enzyme supplemented with 10 µM of the Rho kinase inhibitor (Y-27632) for 15 min at 37 °C. After that, the system added 9 mL of PBS(-) with 0.15% bovine serum albumin fraction V (BSA) to the plate and performed two sets of motion that aspirated 10 mL of cell-containing liquid and dispensed the liquid from the pipette tip in a zig-zag motion across the top of the plate, which was tilted 20° closer to the plate surface, and repeated the above sequence of operations with the plate tilted at 20° on the opposite side. Then, the system collected the cell-containing medium in a 15-mL tube and capped it, after which it was centrifuged at 115 x g for 5 min to deposit the cells. Thereafter, the system aspirated the supernatant and dispersed the cell pellet into single cells using 10 mL of culture medium with 10 µM Y-27632 by pipetting 10 times. The system transferred 1 mL of trypan blue solution into a new 15 mL tube, then added 1 mL of the cell suspension and mixed them by pipetting five times. After that, 100 µL of the Trypan blue-stained cell solution was aspirated and dispensed into the inlet window of the disposable hemocytometer in the holder. The system moved the hemocytometer holder to the microscopic observation area, and captured a photo, which was immediately analyzed by software, and the cell concentration obtained was applied to the next step. For iPSC maintenance, the system seeded the cells at a cell density of 15,000 cells/cm2 in new 10-cm diameter plastic plates coated with 0.5 µg/cm2 cell culture matrix. For differentiation experiments, the system seeded the cells at the required cell density in the medium prepared for each somatic cell type in 6-well plates coated with a cell culture matrix diluted to 1/100. Finally, the system performed cross-locking five times before transferring the plates to the incubator. Three new 10-cm plates containing iPSCs and three cell culture matrix-pre-coated plates were loaded into the system, and other necessary items were also prepared according to the respective procedures mentioned above. One cycle of maintenance culture consists of a passaging task on day 1 followed by a culture medium change once a day for 3 days. All through the experiment, this cycle was set up for five cycles. In addition, consumables were replenished in turn.
According to the ordered schedule, five cycles of maintenance culture were successfully performed as planned by the system. From the cell photographs taken automatically during each task, it was confirmed that the cells proliferated smoothly over time. The cell expansion (n = 3) was calculated and shown in Figure 2. To confirm whether the undifferentiated state of iPSCs remains unchanged even after maintenance culture in the automated culture system, immunocytometoric analysis (Oct3/4 and SSEA4) was performed using the remaining samples at each passaging (Figure 3A). Furthermore, after five cycles, the three dishes were unloaded from the system, and immunohistochemical analysis (Oct3/4, SSEA4, and Tra1-81) was performed as well (Figure 3B). Both analyses using fluorescent immunostaining showed that the undifferentiated state of iPS cells was preserved. Karyotyping of iPSCs was also performed before and after maintenance culture in an automated culture system. Although an abnormality was observed in an allele of chromosome 17 before the start of the maintenance culture, no particular change was observed by the system after 5 maintenance cultures, including the abnormality (Figure 3C). The settings used for maintenance of iPSCs are summarized in Table 1.
Differentiation
Cardiomyocytes
The differentiation protocol from a previous publication was followed here10. The system seeded undifferentiated hiPSCs (KMUR001) at a density of 30,000 cells/cm2 on cell culture matrix-coated 6-well plates in hiPSC culture medium supplemented with 10 µM of Y-27632. The system changed the medium to human pluripotent stem cell medium with 6 µM of the GSK-3ß inhibitor CHIR-99021, 20 ng/mL Activin A, and 10 ng/mL BMP4 after 3 days (differentiation day 1). On differentiation day 3, the system changed to CDM3 medium: RPMI 1640, 500 µg/mL recombinant human albumin, and 213 µg/mL L-ascorbic acid 2-phosphate with 2 µM Wnt-C59. On differentiation day 5, the system changed to fresh CDM3 medium; thereafter, it repeated changing to fresh CDM3 medium every other day. The settings used for cardiomyocyte differentiation of iPSCs are summarized in Table 2.
Hepatocytes
The differentiation protocol from a previous publication was followed here11. The system seeded undifferentiated hiPSCs (RIKEN2F) at a density of 25,000 cells/cm2 on cell culture matrix-coated 6-well plates in hiPSC culture medium supplemented with 10 µM of Y-27632. After 2 days (differentiation day 1), the system changed the medium to RPMI-1640 plus 2% B27 Minus Insulin (RPMI-B27) containing 100 ng/mL Activin A, 6 µM CHIR-99021, and 1% glutamine supplement (e.g., GlutaMAX) for 24 h. On differentiation day 2, we changed the medium to RPMI-B27 with 50 ng/mL Activin A. On differentiation day 5, the system changed the medium to RPMI-B27, containing 1% glutamine supplement and 10 ng/mL BMP-4. On differentiation day 9, the system changed the medium to hepatocyte maturation medium: Leibovitz's L-15 medium containing 8.3% tryptose phosphate broth, 10 µM hydrocortisone 21-hemisuccinate, 50 µg/mL sodium L-ascorbate, 100 nM dexamethasone, 0.58% insulin-transferrin-selenium, 2 mM glutamine supplement, 8.3% fetal bovine serum, and 100 nM rac-1,2-dihexadecylglycerol. Thereafter, the system repeated changing the medium to a fresh medium every other day. The settings used for hepatocyte differentiation of iPSCs are summarized in Table 3.
Neuronal precursor cells
The differentiation protocol from a previous publication was followed here12. The system seeded undifferentiated hiPSCs (RIKEN2F) at a density of 25,000 cells/cm2 on basement membrane matrix-coated 6-well plates in Dulbecco's modified Eagle medium (DMEM)/F12 and neurobasal medium (1:1) supplemented with 10% Knockout serum replacement, 0.1 mM non-essential amino acids, 1 mM glutamine supplement with 10 µM TGF-beta receptor inhibitor (SB431542), 10 µM BMP signal inhibitor (dorsomorphin), and 10 µM Y-27632 (differentiation day 1). On differentiation day 5, the system changed the medium to DMEM/F12 and Neurobasal medium 1:1 supplemented with 0.1mM non-essential amino acids, 1 mM glutamine supplement, 1% N-2 supplement, 1% B-27 supplement, 50 µg/mL ascorbic acid 2-phosphate, 10 µM SB431542, and 10 µM dorsomorphin. On differentiation day 9, the system changed the medium to DMEM/F12 and neurobasal medium 1:1 supplemented with 0.1 mM non-essential amino acids, 1 mM glutamine supplement, 1% N-2 supplement, 1% B-27 supplement, 50 µg/mL ascorbic acid 2-phosphate, and 1 µM all-trans retinoic acid. On differentiation day 13-16, the system changed the medium every day with DMEM/F12 and neurobasal medium 1:1 supplemented with 0.1 mM non-essential amino acids, 1 mM glutamine supplement, 1% N-2 supplement, 1% B-27 supplement, 50 µg/mL ascorbic acid 2-phosphate, and 10 ng/mL bFGF and 10 ng/mL EGF. The settings used for neural precursor cell differentiation of iPSCs are summarized in Table 4.
Keratinocytes
The differentiation protocol from a previous publication was followed here13. The system seeded undifferentiated hiPSCs (253G1) at a density of 15,000 cells/cm2 in cell culture matrix-coated 6-well plates in hiPSC culture medium with 10 µM Y-27632. After 2 days later (differentiation day 1), the system changed the medium to Dulbecco's modified Eagle medium (DMEM)/F12 and Neurobasal medium (1:1) with 0.1 mM non-essential amino acids, 1 mM glutamine, 55 µM 2-mercaptoethanol, 1% N-2 supplement, 2% B-27 supplement, 50 µg/mL ascorbic acid 2-phosphate, 0.05% bovine serum albumin, and 100 ng/mL FGF-basic. On differentiation day 3, and thereafter, the medium was changed to human keratinocyte medium (without supplement for day 3 and with a supplement on/after day 5) with the addition of 0.5 µg/mL hydrocortisone, 1 µM all-trans retinoic acid, 25 ng/mL hBMP-4, 2.4 µg/mL adenine, 1.37 ng/mL triiodothyronine, 0.3 mM ascorbic acid 2-phosphate, and 2 µM forskolin, every 2 days by the system. The settings used for keratinocyte differentiation of iPSCs are summarized in Table 5.
As mentioned above, the entire process was performed using only automated culture equipment, from seeding iPS cells to the subsequent series of differentiation protocols. The expression of characteristic markers in each cell was evaluated (Figure 4). It was shown that differentiation could be induced using only an automated culture system.

Figure 1: Summary of the automated culture system. (A) Picture of the system showing size and layout sketch 1. (B) Picture of the workbench and layout sketch 2. (C) Hand tools: dish, tube, and pipette. This figure has been modified with permission from Bando et al.9. Please click here to view a larger version of this figure.

Figure 2: Passaging task and cell growth. (A) The square illustrates each process. (B) iPSC expansion calculated using every automated cell count in the three independent experiments. (C) Representative images captured automatically from passage to passage. Scale bars = 400 µm and 100 µm (inset). This figure has been modified with permission from Bando et al.9. Please click here to view a larger version of this figure.

Figure 3: Automated long-term maintenance of iPSC. (A) All immunocytometoric analyses of the three independent experiments for Oct-3/4 and SSEA-4. Each blue histogram indicates no primary antibody control. Each red histogram represents the indicated antigen-specific signal. (B) Representative images of immunohistochemically stained cells for Oct-3/4, SSEA-4, and Tra 1-81. Scale bars = 50 µm. (C) Karyotype of the RIKEN2F-iPSC after the fifth passage. This figure has been modified with permission from Bando et al.9. Please click here to view a larger version of this figure.

Figure 4: Immunohistochemical staining. Immunohistochemical pictures of hepatocytes (Scale bars = 100 µm), cardiomyocytes (Scale bars = 100 µm), neuronal progenitor cells (Scale bars = 100 µm), and keratinocytes (Scale bars = 200 µm). This figure has been modified with permission from Bando et al.9. Please click here to view a larger version of this figure.
Table 1: Passage preparations and system settings. Please click here to download this Table.
Table 2: Cardiomyocyte differentiation preparations and system settings. Please click here to download this Table.
Table 3: Hepatocyte differentiation preparations and system settings. Please click here to download this Table.
Table 4: Neural precursor cell differentiation preparations and system settings. Please click here to download this Table.
Table 5: Keratinocyte differentiation preparations and system settings. Please click here to download this Table.